NiloferSabaAzadMD

Oncology • Baltimore, MD

Assistant Professor of Oncology, Johns Hopkins University School of Medicine

Join to view full profile

Dr. Azad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Azad's full profile

Already have an account?

Office
201 North Broadway Street
Viragh BLDG 5th FL
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Baylor College of MedicineResidency, Internal Medicine, 2001 - 2004
Baylor College of MedicineClass of 2001

Certifications & Licensure

MD State Medical License 2008 - 2026
VA State Medical License 2005 - 2026
PA State Medical License 2004 - 2024
NC State Medical License 2020 - 2022
DC State Medical License 2013 - 2016
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014

Clinical Trials

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies Start of enrollment: 2009 Nov 01
Completed
Phase 1
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma Start of enrollment: 2012 Feb 01
Completed
Phase 1
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 15
Completed
Phase 1
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer Start of enrollment: 2017 May 26
Completed
Phase 2
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Start of enrollment: 2018 Feb 07
Active, not recruiting
Phase 1
A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies Start of enrollment: 2019 Jun 06
Terminated
Phase 1
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer Start of enrollment: 2019 Jan 17
Active, not recruiting
Phase 1, Phase 2
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors Start of enrollment: 2019 Apr 17
Active, not recruiting
Phase 1
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer Start of enrollment: 2020 Apr 09
Recruiting
Phase 2
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer Start of enrollment: 2020 May 28
Recruiting
Phase 1
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) Start of enrollment: 2016 May 31
Completed
Phase 2
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Approved for marketing
Roles: Contact
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) Start of enrollment: 2023 Jan 09
Recruiting
Phase 2, Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.
Marina Baretti, Soumya Shekhar, Vaibhav Sahai, Daniel Shu, Kathryn Howe
Hepatology Communications. 2025-03-01
Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.
Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, Li Chen, Michael J Overman
Clinical Cancer Research. 2025-02-17
Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer ...
Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, Nilofer S Azad, May Cho
Cancer. 2025-02-15

Lectures

What Is Working in Clinical Trial Recruitment? - Panel Moderator
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Drug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 15th, 2024
Drug Combination Boosts Immune Response in Resistant Pancreatic CancersNovember 15th, 2024
Drug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 14th, 2024
Join now to see all